Given CtBP's robust validation as a cancer therapeutic target in multiple in vivo systems, we have developed a library of CtBP dehydrogenase substrate competitive inhibitors (CtBPi) in an effort to therapeutically inactivate CtBP's oncogenic functions. This evidence concerns the gene CTBP1 and cancer.